OPKO Health, Inc. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
OPKO Health, Inc. (OPK) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $172.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2023-02-27
- OPKO Health, Inc. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2022-12-31 was $0.00.
- OPKO Health, Inc. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2022-09-30 was $0.00.
- OPKO Health, Inc. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2021-12-31 was $0.00.
- OPKO Health, Inc. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2021-09-30 was $0.00.
- OPKO Health, Inc. business combination, consideration transferred, equity interests issued and issuable for fiscal 2022 was $172.00M.
- OPKO Health, Inc. business combination, consideration transferred, equity interests issued and issuable for fiscal 2021 was $0.00.
- OPKO Health, Inc. business combination, consideration transferred, equity interests issued and issuable for fiscal 2020 was $0.00.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 6 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 9 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $172.00M 10-K · filed 2023-02-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $172.00M 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $172.00M 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |